ABVX three-lens brief
Evidence-based stock research on ABVX. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Currently unprofitable on a trailing basis — no P/E multiple available.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $163.58 — 79% above current (12 analysts).
- Negative free cash flow last quarterly (-$125.90M).
ABVX closed at $91.44 (+1.60%) as of 2026-11-12. Market cap: $8.00B. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $163.58 — 79% above current (12 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.; currently unprofitable on a trailing basis — no P/E multiple available.. Last quarter: Revenue $1.20M, net income -$117.43M, free cash flow -$125.90M.
Why three lenses on ABVX, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ABVX across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/ABVX" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ABVX brief"></iframe>